Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Jorge L Alió, EGS 2020 – Corneal Regeneration, Will It Be a Reality in 2021?

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Jan 14th 2021

We were delighted to talk with our Editorial Board member, Jorge L. Alió (Miguel Hernández University of Alicante, Elche, Spain) about the recent technological advances in corneal regeneration.

Questions

  1. Could you tell us a little about the challenges and opportunities of corneal regeneration? (0:05)
  2. What have been the most exciting recent technological advances in corneal regeneration? (1:03)
  3. Could you tell us a little about your experiences with corneal regeneration? (4:37)

Disclosures: Jorge L Alió  has nothing to disclose in relation to this video.

Support: Interview and filming supported by Touch Medical Media Ltd.

Filmed in coverage of EGS 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup